Psilocybin, derived from “magic mushrooms,” has shown potential in promoting dendritic spine formation, a critical aspect of synaptic plasticity. Studies suggest that psilocybin can alleviate depression and anxiety, even in treatment-resistant cases, and may help restore emotional well-being in AD patients. Additionally, psilocybin’s effects on serotonin signaling may help reduce the amyloid burden and neuroinflammation associated with AD.